T W Synold
Overview
Explore the profile of T W Synold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Tetef M, Synold T, Chow W, Leong L, Margolin K, Morgan R, et al.
Clin Cancer Res
. 2001 Jun;
7(6):1569-76.
PMID: 11410492
Dexrazoxane is a bidentate chelator of divalent cations. Pretreatment with short infusions of dexrazoxane prior to bolus doxorubicin has been shown to lessen the incidence and severity of anthracycline-associated cardiac...
12.
Synold T, Dussault I, Forman B
Nat Med
. 2001 May;
7(5):584-90.
PMID: 11329060
Cytochrome P450 3A4 is an important mediator of drug catabolism that can be regulated by the steroid and xenobiotic receptor (SXR). We show here that SXR also regulates drug efflux...
13.
Doroshow J, Synold T, Somlo G, Akman S, Gajewski E
Blood
. 2001 Apr;
97(9):2839-45.
PMID: 11313279
In prior studies, it was demonstrated that the redox metabolism of doxorubicin leads to the formation of promutagenic oxidized DNA bases in human chromatin, suggesting a potential mechanism for doxorubicin-related...
14.
Raschko J, Synold T, Chow W, Coluzzi P, Hamasaki V, Leong L, et al.
Cancer Chemother Pharmacol
. 2000 Dec;
46(5):403-10.
PMID: 11127945
Purpose: In recognition of the variety of available chemotherapeutic modulating agents and their potential to enhance the efficacy of platinum-based therapy, we embarked upon a phase I study to investigate...
15.
McLeod H, Cassidy J, Powrie R, Priest D, Zorbas M, Synold T, et al.
Clin Cancer Res
. 2000 Jul;
6(7):2677-84.
PMID: 10914709
Glycinamide ribonucleotide formyltransferase (GARFT) is a component of the de novo purine synthesis pathway. AG2034 is a specific inhibitor of GARFT that was designed based on the GARFT crystal structure....
16.
Synold T, Newman E, Carroll M, Muggia F, Groshen S, Johnson K, et al.
Clin Cancer Res
. 1998 Oct;
4(10):2349-55.
PMID: 9796964
Lometrexol inhibits the first folate-dependent enzyme in de novo purine biosynthesis and is avidly polyglutamated and retained in tissues expressing folylpolyglutamate synthetase. Although clinical studies have been limited by cumulative...
17.
Synold T, Tetef M, Doroshow J
Semin Oncol
. 1998 Oct;
25(4 Suppl 10):93-9.
PMID: 9768830
Although originally developed as an antitumor agent in the 1970s, dexrazoxane (DEX) is currently used as a cardioprotective agent in combination with doxorubicin (DOX). Due to concerns about anthracycline-induced cardiotoxicity...
18.
Lum B, Lane K, Synold T, Goram A, Charnick S, Sikic B
Pharmacotherapy
. 1997 Nov;
17(5):887-90.
PMID: 9324178
Study Objective: To validate the utility of a previously reported 3-point limited sampling model (LSM) for determining etoposide area under the curve to infinity (AUC(infinity)). Design: Secondary analysis of data...
19.
Galpin A, Schuetz J, Masson E, Yanishevski Y, Synold T, Barredo J, et al.
Mol Pharmacol
. 1997 Jul;
52(1):155-63.
PMID: 9224825
Cellular accumulation of methotrexate polyglutamates (MTXPGs) is recognized as an important determinant of the cytotoxicity and selectivity of methotrexate in acute lymphoblastic leukemia (ALL). We identified a significantly lower cellular...
20.
Muggia F, Synold T, Newman E, Jeffers S, Leichman L, Doroshow J, et al.
J Natl Cancer Inst
. 1996 Oct;
88(20):1495-6.
PMID: 8841028
No abstract available.